News & Updates

Patients with previously untreated, locally advanced, or metastatic squamous non-small-cell lung cancer (NSCLC) may derive benefit from the addition of the novel anti-PD-1 monoclonal antibody serplulimab to chemotherapy, according to the final analysis of the phase III ASTRUM-004 study.

Trastuzumab deruxtecan (T-DXd) at both 5.4 mg/kg and 6.4 mg/kg doses provides clinically meaningful and durable responses in patients with previously treated HER2-mutant (HER2m) metastatic non-small-cell lung cancer (mNSCLC), with the 5.4 mg/kg dose showing a more favourable benefit/risk profile, according to primary results of the phase II DESTINY-Lung02 trial.

Visceral fat area (VFA) is a reliable prognostic indicator of muscle mass and is associated with nutritional, immune, and inflammatory status in patients with diverse types of cancer, such as gastric, colorectal, and nonsmall-cell lung cancers (NSCLC), claims a recent study.

In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).

Pretreatment level of serum carcinoembryonic antigen (CEA) is independently associated with overall and disease-free survival among patients with nonsmall cell lung cancer (NSCLC), reports a study. The same marker is also used for the prognosis of patients with the same pathologic stages.

Patients with nonerosive gastroesophageal reflux disease (GERD) show no higher incidence of esophageal adenocarcinoma (EAC) when compared with the general population, according to a study.